Evidence map›Paper›PMID 42719784›Full record

ArticleJournal of functional foods2026

Sakuranetin modulates estrogen receptor signaling in breast cancer cells.

Jorge A Belgodere, Britney Nguyen, Anna M Hardgrove, Stephen W Wheat, Isaac J Ponder, Geoffroy E R Sanga Pema, Julianne G Heath, William Broussard, Sophie R Dietrich, Steven Elliott and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of functional foods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jorge A BelgodereTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Britney NguyenDepartment of Biological and Agricultural Engineering, Louisiana State University and Agricultural Center, Baton Rouge, Louisiana 70803, USA.
Anna M HardgroveDepartment of Biological and Agricultural Engineering, Louisiana State University and Agricultural Center, Baton Rouge, Louisiana 70803, USA.
Stephen W WheatTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Isaac J PonderDepartment of Biological and Agricultural Engineering, Louisiana State University and Agricultural Center, Baton Rouge, Louisiana 70803, USA.
Geoffroy E R Sanga PemaTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Julianne G HeathTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
William BroussardOak Ridge Institute for Science and Education, U.S. Department of Energy, Oak Ridge, TN, USA.
Sophie R DietrichTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Steven ElliottTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Syreeta L TilghmanPharmaceutical Sciences Division, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA.
Muralidharan AnbalaganTulane Cancer Center, Tulane University, New Orleans, LA 70112, USA.
Brian G RowanTulane Cancer Center, Tulane University, New Orleans, LA 70112, USA.
Bridgette M Collins-BurowTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Simak AliDepartment of Surgery and Cancer, Imperial College London Hammersmith Hospital Campus London, W12 0NN, UK.
Van H BarnesTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Elizabeth C MartinTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.
Jayalakshmi SridharDepartment of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA.
Stephen M BouéU. S. Department of Agriculture, Agricultural Research Service, Southern Regional Research Center, New Orleans, LA 70179, USA.
Matthew E BurowTulane Department of Medicine, Section of Hematology & Medical Oncology, Tulane University Health Science Center, New Orleans, LA 70112, USA.

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
CTSA K12 Program at the University of Alabama at BirminghamK12TR004769 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Renee A. Heffron, Lucio Miele · 2024 to 2026
$4.8M
Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer (Diversity Supplement - Belgodere)R01CA273095 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUROW, MATTHEW E., DREWRY, DAVID HAROLD · 2022 to 2025
$2.9M
NCATS NIH HHS K12 TR004769NCI NIH HHS R01 CA273095NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

Identification of natural, bioactive compounds has been of interest to the biomedical field, in particular for the treatment of cancer. Flavonoids are a family of compounds, present across many plant species, known for their polyphenolic structure that results in cellular bioactivity. The flavonoid, sakuranetin, is produced due to external stressors, through the naringenin biosynthetic pathway. Binding affinity and docking simulations confirmed sakuranetin binding to the estrogen receptor alpha (ERα) pocket in a manner similar to, but with weaker affinity than 17β-estradiol (E2). Due to sakuranetin having chemical similarities to estrogen, this study evaluated the potential of sakuranetin to act as an endocrine modulator in estrogen receptor-positive (ERα+) breast cancer cell lines. In the ERα + cell lines, MCF-7 and T-47D, sakuranetin treatment induced dose-dependent estrogenic activity (≥ 10 μM). Sakuranetin significantly increased colony formation and cell proliferation in the MCF-7 cell line. Breast cancer cell lines with constitutively active ER through an inserted mutation in the ERα (Y537S) demonstrated no significant changes in estrogenic activity or cellular proliferation following sakuranetin treatment, except at an elevated dose (50 μM). Finaly, sakuranetin treatment enhanced genes associated with ER signaling and significantly increased ERα-mediated gene (PGR and CXCL12) expression. These results support the role of sakuranetin as a natural estrogenic compound.

Indexed as

Estrogen activityFlavonoidsNaringeninSakuranetin

Identifiers

PMID42719784
PMCPMC13556995

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.